This content is machine translated Multiple sclerosis Vitamin D as an adjuvant in multiple sclerosis: statistical success and clinical limitations Various risk factors are involved in the pathogenesis of multiple sclerosis, with vitamin D deficiency being associated with an increased risk of MS since the 1970s. Disease-modifying therapies aim to...…
View Post 6 min This content is machine translated Chronic insomnia in adults: Guideline recommendations CBT-i as first choice – pharmacotherapy as secondary intervention Sleep disorders are often associated with pronounced daytime sleepiness, difficulty concentrating and increased feelings of stress. Diagnosis is generally based on the clinical history; if necessary, an actigraphy or polysomnigraphy...…
View Post 4 min Education Geriatrics Neurology Pharmacology and toxicology RX Studies Opicapon: double benefit for motor function and sleep in Parkinson’s disease Sleep disorders are among the most common non-motor Parkinson’s symptoms. The targeted treatment of sleep disorders is an important part of Parkinson’s therapy and can significantly improve quality of life....…
View Post 5 min This content is machine translated Multiple sclerosis Avoiding the nocebo trap with natalizumab biosimilars Monoclonal antibodies such as natalizumab are indispensable for multiple sclerosis therapy. A first recently approved biosimilar is clinically equivalent, as studies have shown. Nevertheless, reservations are widespread in practice. Patients...…
View Post 9 min This content is machine translated Psoriasis: intervening in the inflammatory cascade Advantages of early biologic therapy and oral peptide as a beacon of hope The question of whether early biologics treatment can have a lasting effect on the course of psoriasis is the focus of numerous research projects. The GUIDE study investigated the corresponding...…
View Post 4 min This content is machine translated Bipolar disorder, anxiety disorder, depression Lurasidone as monotherapy for bipolar I depression with anxiety symptoms Comorbid anxiety is common in patients with bipolar disorder. This comorbidity is associated with increased disease severity and poorer treatment response. A study with lurasidone 20-60 mg/day showed significant efficacy...…
View Post 4 min This content is machine translated GLP1-RA therapy Improvement in either weight or HbA1c – but never both Numerous studies show that glucagon-like peptide-1 receptor agonists (GLP1-RA) can significantly reduce the risk of diabetes-related complications and also reduce mortality. Despite their proven efficacy in trial designs, patient response...…
View Post 6 min This content is machine translated Suicide Dealing with trauma after suicide loss: What do bereaved people experience as effective? Every year, over 100 million people around the world are affected by suicide. Survivors often experience long-lasting, severe trauma and have an increased risk of mental illness and suicidal thoughts...…
View Post 6 min This content is machine translated Galenic systems Advantages of topical pharmacotherapy – Update 2025 Topical pharmacotherapies offer the unique advantage that the products are applied directly to the diseased skin, resulting in local, distinctly direct contact between the product and the affected skin. The...… CME-Test
View Post 45 min This content is machine translated Psychedelics and related drug classes Ritual, party or new therapy? Psychedelics and more: clinically illuminated Psychedelika und angrenzende Wirkstoffklassen wie Entaktogene und Dissoziativa bewegen sich zwischen Ritual, Freizeitkultur und klinischer Anwendung, meist in unterschiedlichen Phasen der Erforschung. Sie werden in verschiedensten Formen, Dosen und Kontexten...… CME-Test
View Post 5 min This content is machine translated "Survey of Health, Ageing and Retirement in Europe" (SHARE) Analysis of polypharmacy in ≥65-year-olds The SHARE study is an international multidisciplinary longitudinal survey. The panel survey has been conducted approximately every other year for over 20 years. In an analysis published in 2025, data...…
